RBR-3875dd
Recruiting
未知
Immunogenicity and safety of primary yellow fever vaccination in patients with rheumatic diseases
Hospital Universitário Cassiano Antônio de Moraes0 sitesMarch 5, 2020
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- C20.111
- Sponsor
- Hospital Universitário Cassiano Antônio de Moraes
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The present study included patients with rheumatic diseases including Rheumatoid Arthritis, Systemic Erythematosus Lupus, Sjögren Syndrome, Systemic Sclerosis and Spondylarthritis over 18 years of age who received yellow fever 17DD anti\-mammalian first vaccination in the 2017 Brazilian Campaign from January until December 2017\. The control group consisted of individuals who spontaneously searched the Rheumatology Service of HUCAM to receive yellow fever first vacination YF 17DD antimammalian Biomanguinhos\-FIOCRUZ in the 2017 Brazilian Campaign and who did not have immune mediated rheumatic disease and no history of previous yellow fever vaccination.
Exclusion Criteria
- •Exclusion criteria included patients under 18 years of age, patients with history of previous yellow fever vaccination, patients external to HUCAM who have not been referred by a rheumatologist by letter or direct contact of the attending physician indicating the diagnosis and medications in use, those who do not agree to participate; patients immunosuppressed by other causes such as HIV infected, CD4 count less than 200 cells per mm3, organ transplantation history, primary immunodeficiency, neoplasia, previous history of timus disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study of Yellow Fever Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and PeruPrevention of symptomatic dengue diseaseTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2014-001714-26-Outside-EU/EEASanofi Pasteur SA792
Not yet recruiting
Not Applicable
Immunity induced by yellow fever vaccination in the elderly (60yrs or older)travellergele koorts, oudere, reizen, neutraliserende antistoffen, bijwerkingenyellow fever, elderly, travel, neutralizing antibodies, adverse eventsNL-OMON20831A.H.E. Roukens en L.G. Visser60
Unknown
Not Applicable
IMMUNOGENICITY AND SAFETY OF YELLOW FEVER VACCINE (STAMARIL®) ADMINISTERED CONCOMITANTLY WITH TETRAVALENT DENGUE VACCINE IN HEALTHY TODDLERS AT 12-13 MONTHS OF AGE IN COLOMBIA AND PERPER-037-11SANOFI PASTEUR INC.,320
Completed
Not Applicable
ong-term immunity after Yellow fever vaccinatioYellow feverJPRN-UMIN000040526Tokyo Medical University Hospital Travellers' Medical Center50
Completed
Phase 4
Human Immune Responses to Yellow Fever VaccinationYellow FeverNCT00694655Emory University239